amifostine anhydrous has been researched along with Cancer of Cervix in 18 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria." | 2.75 | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. ( Bai, M; Batistatou, A; Briasoulis, E; Capizzello, A; Christodoulou, D; Karavasilis, V; Katsanos, KH; Panelos, I; Tolis, C; Tsekeris, P; Tsianos, EV, 2010) |
| "Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily x 5 schedule." | 2.67 | Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. ( Beitler, JJ; Bruckner, H; Goldberg, G; Haynes, H; Hochster, H; Holland, JF; Mandeli, J; Runowicz, C; Smith, H; Wadler, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katsanos, KH | 1 |
| Briasoulis, E | 1 |
| Tsekeris, P | 1 |
| Batistatou, A | 1 |
| Bai, M | 1 |
| Tolis, C | 1 |
| Capizzello, A | 1 |
| Panelos, I | 1 |
| Karavasilis, V | 1 |
| Christodoulou, D | 1 |
| Tsianos, EV | 1 |
| Bourhis, J | 1 |
| Blanchard, P | 1 |
| Maillard, E | 1 |
| Brizel, DM | 1 |
| Movsas, B | 1 |
| Buentzel, J | 1 |
| Langendijk, JA | 1 |
| Komaki, R | 1 |
| Swan Leong, S | 1 |
| Levendag, P | 1 |
| Pignon, JP | 1 |
| Small, W | 5 |
| Winter, K | 1 |
| Levenback, C | 1 |
| Iyer, R | 1 |
| Hymes, SR | 1 |
| Jhingran, A | 1 |
| Gaffney, D | 1 |
| Erickson, B | 1 |
| Greven, K | 1 |
| Kouvaris, J | 1 |
| Kouloulias, V | 1 |
| Malas, E | 1 |
| Antypas, C | 1 |
| Kokakis, J | 1 |
| Michopoulos, S | 1 |
| Matsopoulos, G | 1 |
| Vlahos, L | 1 |
| De Los Santos, JF | 1 |
| Takahashi, M | 2 |
| Abe, M | 1 |
| Kawamura, T | 1 |
| Iio, A | 1 |
| Hamamoto, K | 1 |
| Inohara, T | 1 |
| Rubin, JS | 2 |
| Wadler, S | 4 |
| Beitler, JJ | 4 |
| Haynes, H | 4 |
| Rozenblit, A | 2 |
| McGill, F | 2 |
| Goldberg, G | 4 |
| Runowicz, C | 4 |
| Mitsuhashi, N | 2 |
| Takahashi, I | 2 |
| Hayakawa, K | 1 |
| Niibe, H | 2 |
| Cohen, C | 1 |
| Speyer, J | 1 |
| Holland, JF | 1 |
| Hochster, H | 1 |
| Bruckner, H | 1 |
| Mandeli, J | 1 |
| Smith, H | 1 |
| Fields, A | 1 |
| Anderson, P | 1 |
| Sood, B | 1 |
| Mehta, MP | 1 |
| Blohmer, JU | 1 |
| Paepke, S | 1 |
| Böhmer, D | 1 |
| Ernhardt, B | 1 |
| Sehouli, J | 1 |
| Elling, D | 1 |
| Lichtenegger, W | 1 |
| Miyaishi, K | 1 |
| Maehara, Y | 1 |
| Nakajima, N | 1 |
| Suto, H | 1 |
| Saito, Y | 1 |
| Yamakawa, M | 1 |
| Sugiyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes[NCT00012012] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The second part of this study (second arm) was designed to detect a 40% relative reduction (absolute from 77% to 46%) in the acute grade 3/4 toxicity (excluding grade 3 leukopenia) rate, with the addition of amifostine. A one-sided alpha of 0.05 and 80% power required 16 evaluable patients to detect the hypothesized difference. If ≤ 8 had the toxicity, it would be concluded that adding amifostine decreased this toxicity rate by at least 40%. (NCT00012012)
Timeframe: From start of treatment to 90 days
| Intervention | participants (Number) |
|---|---|
| Radiation Therapy Plus Cisplatin and Amifostine | 13 |
To determine the feasibility and tolerance of extended-field external radiotherapy to the pelvis and para-aortic region and intracavitary irradiation combined with weekly cisplatin using the rate of acute grade 3/4 toxicity rate (excluding grade 3 leukopenia). The first part of this study was designed to determine the acute grade 3/4 toxicity rate (excluding grade 3 leukopenia), to have a starting point for the second part (second arm) of the study. (NCT00012012)
Timeframe: From start of treatment to 90 days
| Intervention | percentage of participants (Number) |
|---|---|
| Radiation Therapy Plus Cisplatin | 81 |
6 reviews available for amifostine anhydrous and Cancer of Cervix
| Article | Year |
|---|---|
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-S | 2011 |
Potential for use of amifostine in cervical cancer.
Topics: Amifostine; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Ph | 2002 |
The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.
Topics: Amifostine; Clinical Trials as Topic; Combined Modality Therapy; Cryoprotective Agents; Female; Huma | 2004 |
The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Topics: Amifostine; Antineoplastic Agents; Brachytherapy; Cisplatin; Clinical Trials as Topic; Combined Moda | 1996 |
Amifostine and combined-modality therapeutic approaches.
Topics: Amifostine; Clinical Trials as Topic; Combined Modality Therapy; Cytoprotection; Female; Head and Ne | 1999 |
The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fe | 2002 |
9 trials available for amifostine anhydrous and Cancer of Cervix
| Article | Year |
|---|---|
Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
Topics: Adult; Aged; Amifostine; Colitis; Combined Modality Therapy; Endometrial Neoplasms; Female; Follow-U | 2010 |
Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Brachytherapy; Carcinoma; Cisplatin; Female; Humans; | 2011 |
Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Topics: Aged; Amifostine; Chi-Square Distribution; Data Interpretation, Statistical; Endometrial Neoplasms; | 2003 |
Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.
Topics: Amifostine; Antineoplastic Agents; Brachytherapy; Cisplatin; Combined Modality Therapy; Female; Huma | 2003 |
Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.
Topics: Amifostine; Antineoplastic Agents; Audiometry; Cisplatin; Combined Modality Therapy; Drug Tolerance; | 1995 |
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combine | 1993 |
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group.
Topics: Adult; Aged; Amifostine; Calcitriol; Calcium; Calcium, Dietary; Cisplatin; Combined Modality Therapy | 1993 |
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study].
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2001 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
3 other studies available for amifostine anhydrous and Cancer of Cervix
| Article | Year |
|---|---|
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung | 2002 |
[Radioprotective effect of YM-08310 in radiotherapy of cervical cancer].
Topics: Adult; Aged; Amifostine; Blood Cell Count; Double-Blind Method; Drug Evaluation; Female; Humans; Mid | 1982 |
Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Incidence; Infusion | 1993 |